For this reason, pharmacological CaSR inhibition with specific calcilytics has gained interest in recent years as a possible treatment and mitigation of aberrant inflammatory stimuli, which are usually observed in diseases such as asthma, Alzheimer’s disease, obesity, and inflammatory bowel diseases; and, by extension, for the treatment and/or management of sepsis, burn injuries and rheumatoid arthritis. Here, CASR is linked to rheumatoid arthritis.